NRG1 and neoplasm: First, gene fusions are considered strong oncogenic drivers and recent clinical data show strong efficacy of compounds targeting, e.g., neuregulin 1 (NRG1) [150,151,152], neurotrophic tyrosine kinase receptor (NTRK) [152,153] or anaplastic lymphoma kinase (ALK) [154,155] fusions in patients across various tumor types.